Drug updated on 10/23/2023
|Emulsion (topical: 0.5 mg/mL)
|Calcineurin inhibitor immunosuppressant
|Ongoing and Completed Studies
- Indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.
Product Monograph / Prescribing Information
|Restasis (cyclosporine ophthalmic emulsion) Prescribing Information.
|Allergan, Irvine, CA, U.S.A
Systematic Reviews / Meta-Analyses
|Efficacy of topical ophthalmic drugs in the treatment of dry eye disease: a systematic literature review.
|The Ocular Surface